NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock.

NovaBay Pharmaceuticals Trading Down 6.4 %

Shares of NBY stock opened at $0.14 on Friday. The firm has a market cap of $937,708.00, a P/E ratio of -0.02 and a beta of 2.02. NovaBay Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $2.60. The stock’s 50 day moving average is $0.20.

About NovaBay Pharmaceuticals

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.

See Also

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.